Genmab A/S (GMAB) Stock Score, Valuation & Financial Research
Genmab A/S is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 33/100.
Quick answer for GMAB
Genmab A/S currently has a Wall Street Score of 33/100. The stored market price is $32.47. Its financial score is 12/100. Its valuation score is 16/100. The latest WSS change is -0.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What Genmab A/S does
Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-C
GMAB financial snapshot
- Wall Street Score:
- 33/100
- Current price:
- $32.47
- Market capitalization:
- $19.93B
- Revenue:
- $4.13B
- Net income:
- $788.1M
- Free cash flow:
- $1.15B
- Cash:
- $1.50B
- Total debt:
- $5.27B
- EPS:
- 1.55
- P/E ratio:
- 20.9x
- Financial score:
- 12/100
- Valuation score:
- 16/100
- Revenue score:
- 25/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $1.15B, showing positive cash generation.
- The balance sheet shows $1.50B of cash versus $5.27B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.4 points: GMAB decreased 0.4 points because Capital declined by 4 points, Valuation declined by 5 points.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 12/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GMAB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.